Evaluating latency reactivation synergies between the bromodomain inhibitor iBET-151 and the SMAC mimetic AZD5582 in SIV-infected macaques on ART

• A.A. Okoye,
• Y. Fukazawa,
• B.E. Randall,
• R. Lum,
• B. Varco-Merth,
• S.D. Falcinelli,
• J. Smedley,
• R. Dunham,
• J.D. Lifson,
• L.J. Picker

Affiliations

A.A. Okoye

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

Y. Fukazawa

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

B.E. Randall

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

R. Lum

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

B. Varco-Merth

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

S.D. Falcinelli

UNC HIV Cure Center, University of North Carolina at Chapel Hill and HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, Nc, USA

J. Smedley

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA

R. Dunham

UNC HIV Cure Center, University of North Carolina at Chapel Hill and HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, Nc, USA

J.D. Lifson

AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, Md, USA

L.J. Picker

Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Or, USA